Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: A nationwide cohort study

European Heart Journal

Volumn 33, Issue 20, 2012, Pages 2527-2534

  Charlot, Mette ^a   Nielsen, Lars Hougaard ^b   Lindhardsen, Jesper ^a   Ahlehoff, Ole ^a   Olsen, Anne Marie S ^a   Hansen, Morten Lock ^a   Hansen, Peter Riis ^a   Madsen, Jan Kyst ^a   Kober, Lars ^c   Gislason, Gunnar H ^a   Torp Pedersen, Christian ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Clopidogrel; Epidemiology; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMORBIDITY; DEATH; DIABETES MELLITUS; DRUG USE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PEPTIC ULCER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SHOCK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOSIS; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADULT; AGED; DENMARK; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; GRAFT OCCLUSION, VASCULAR; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS FAILURE; RECURRENCE; STENTS; THROMBOSIS; TICLOPIDINE; WITHHOLDING TREATMENT;

EID: 84867714999     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs202     Document Type: Article

References (34)

1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157.
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
3. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420.
4. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358: 527-533.
5. Harrington RA, Califf RM. Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried? J Am Coll Cardiol 2006;48: 2592-2595.
6. Sambu N, Warner T, Curzen N. Clopidogrel withdrawal: is there a "rebound" phenomenon? Thromb Haemost 2011;105:211-220.
7. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168.
8. Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS. Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization. JACC Cardiovasc Interv 2009;2:1279-1285.
9. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010;362:1374-1382.
10. Dean J, Yujie Z, Yingxin Z, Yuyang L, Yonghe G, Wanjun C, Zheng C. Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents. Clin Cardiol 2009;32:164-168.
11. Banerjee S, Varghese C, Samuel J, Weideman RA, Little BB, Kelly KC, Rao SV, Reilly RF, Brilakis ES. Comparison of the impact of short (,1 year) and long-term (. or ¼1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol 2008;102:1159-1162.
12. Butler MJ, Eccleston D, Clark DJ, Ajani AE, Andrianopoulos N, Brennan A, New G, Black A, Szto G, Reid CM, Yan BP, Shaw JA, Dart AM, Duffy SJ. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. Am Heart J 2009;157:899-907.
13. Harjai KJ, Shenoy C, Orshaw P, Boura J. Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry. Heart 2009;95:1579-1586.
14. Tanzilli G, Greco C, Pelliccia F, Pasceri V, Barilla F, Paravati V, Pannitteri G, Gaudio C, Mangieri E. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am J Cardiol 2009;104: 1357-1361.
15. Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, Hansen PR, Madsen JK, Kober L, Torp-Pedersen C, Gislason G. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010;153:378-386.
16. Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, Rasmussen S, Kober L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153-1158.
17. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-448.
18. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124-130.
19. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol 2001;37:992-997.
20. Park D-W, Park S-W, Park K-H, Lee B-K, Kim Y-H, Lee CW, Hong M-K, Kim J-J, Park S-J. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-356.
21. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L. Longterm outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
22. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HHT, Bottcher M, Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Soerensen HT, Thuesen L. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007;50:463-470.
23. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948.
24. Roukoz H, Bavry AA, Sarkees ML, Mood GR, Kumbhani DJ, Rabbat MG, Bhatt DL. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med 2009;122:581 e1-10.
25. Harrington RA, Ohman EM. The enigma of drug-eluting stents: hope, hype, humility, and advancing patient care. JAMA 2007;297:2028-2030.
26. vanWerkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JH, Hautvast RW, Verheugt FW, ten Berg JM. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-1409.
27. Rossini R, Capodanno D, Lettieri C, Musumeci G, Nijaradze T, Romano M, Lortkipanidze N, Cicorella N, Biondi Zoccai G, Sirbu V, Izzo A, Guagliumi G, Valsecchi O, Gavazzi A, Angiolillo DJ. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011;107:186-194.
28. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009;119:987-995.
29. Collet J-P, Montalescot G, Steg PG, Steinhubl SR, Fox KAA, Hu TF, Johnston SC, Hamm CW, Bhatt DL, Topol EJ. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis 2009;102:485-496.
30. Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-539.
31. Ho PM, Tsai TT, Wang TY, Shetterly SM, Clarke CL, Go AS, Sedrakyan A, Rumsfeld JS, Peterson ED, Magid DJ. Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: insights from a large integrated healthcare delivery system. Circ Cardiovasc Qual Outcomes 2010;3:303-308.
32. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, doubleblind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-1041, 41 e1.
33. Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann FJ, ten Berg JM, Schomig A, Kastrati A. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 2009;157:620-624 e2.
34. Quadros AS, Welter DI, Camozzatto FO, Chaves Á, Mehta RH, Gottschall CA, Lopes RD. Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation. Am J Cardiol 2011;107:685-689.